[Skip to Content]
[Skip to Content Landing]
Views 2,408
Citations 0
Research Letter
December 15, 2016

Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology

Author Affiliations
  • 1Department of Medicine, University of Washington, Seattle
  • 2Center for Cancer Innovation, University of Washington, Seattle
  • 3Northwest Medical Specialties, Puyallup, Washington
  • 4 Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 5Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle
JAMA Oncol. Published online December 15, 2016. doi:10.1001/jamaoncol.2016.4983

The growing use of next generation-sequencing to identify cancer-associated alterations as well as the increasing number of targeted drugs holds promise for better matching patients with cancer with effective therapies. The FoundationOne (F1; Foundation Medicine) test sequences clinical tumor samples to characterize the exons of 315 cancer-associated genes and introns from 28 genes involved in rearrangements. The Guardant360 (G360; Guardant Health) test uses cell-free circulating DNA from blood to sequence 70 genes. Both the F1 and G360 tests have high specificities (>99%) and somewhat lower sensitivities.1,2 However, little is known about how different next-generation sequencing tests compare when used in the same patients with cancer. We compared reports from F1 and G360 testing in 9 patients from a community oncology practice to determine the level of concordance between the platforms.

First Page Preview View Large
First page PDF preview
First page PDF preview